Cancer Statistics, CA Cancer J Clin, vol.67, pp.7-30, 2017. ,
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, pp.2913-2921, 2014. ,
More deaths from pancreatic cancer than breast cancer in the EU by 2017, Acta Oncol, vol.55, pp.1158-1160, 2016. ,
Pancreatic cancer, Lancet, vol.10039, pp.73-85, 2016. ,
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1825, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
,
Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine, N Engl J Med, vol.369, pp.1691-1703, 2013. ,
,
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis, Lancet Oncol, vol.17, pp.801-810, 2016. ,
, , pp.172-180
Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC), J Clin Oncol, vol.36, 2018. ,
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort, Ann Surg Oncol, vol.22, pp.295-301, 2015. ,
, NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version, vol.1, 2018.
, A randomized phase III trial comparing Folfirinox to gemcitabine in locally advanced pancreatic carcinoma (NEOPAN), 2019.
FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med, vol.379, pp.2395-2406, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02281628
,
Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX, Am J Clin Oncol, vol.40, pp.507-511, 2017. ,
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors, Int J Cancer, vol.139, pp.938-945, 2016. ,
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma, Pancreas, vol.42, pp.1311-1315, 2013. ,
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer, Oncologist, vol.20, pp.143-150, 2015. ,
,
Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP), Br J Cancer, vol.115, pp.281-289, 2016. ,
Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer, Ann Oncol, vol.28, issue.Suppl_3, pp.137-186, 2017. ,
Can nomograms be superior to other prediction tools?, BJU Int, vol.103, pp.492-495, 2009. ,
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis, J Natl Cancer Inst, vol.103, pp.21-30, 2011. ,
Understanding and communicating measures of treatment effect on survival: can we do better?, J Natl Cancer Inst, vol.110, pp.232-240, 2018. ,
Impact of prognostic discussions on the patient-physician relationship: prospective cohort study, J Clin Oncol, vol.36, pp.225-230, 2018. ,
Overall survival prediction and usefulness of secondline chemotherapy in advanced pancreatic adenocarcinoma, J Natl Cancer Inst, vol.109, issue.10, 2017. ,
Cancer survival: an overview of measures, uses, and interpretation, J Natl Cancer Inst Monogr, vol.2014, p.97, 2014. ,
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma, Ann Oncol, vol.28, pp.2786-2792, 2017. ,
Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy, Int J Clin Oncol, vol.21, pp.118-125, 2016. ,
,
FOLFIRINOX and translational studies: towards personalized therapy in pancreatic cancer, World J Gastroenterol, vol.22, pp.6987-6700, 2016. ,
,
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study, BMC Cancer, vol.18, p.1185, 2018. ,
,
, NLR, neutrophil-to-lymphocyte ratio
, PLR, platelet-to-lymphocyte ratio